Keryx Biopharmaceuticals Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2017. Total revenues for the quarter ended March 31, 2017 were $11.8 million, compared with $6.8 million during the same period in 2016. Total revenues for the first quarter of 2017 consist of $10.5 million in net U.S. Auryxia product sales, compared to $5.6 million in the first quarter of 2016. Total revenue for the first quarter of 2017 also includes $1.3 million in license revenues as compared to $1.2 million during the same period in 2016. Net loss for the quarter ended March 31, 2017 was $23.0 million, or $0.21 per share, compared to a net loss of $41.0 million, or $0.39 per share, for the comparable period in 2016. Loss before income taxes was $40.944 million against $27.717 million a year ago. Operating loss was $23.110 million compared to $23.397 million a year ago. Loss before income taxes was $22.9 million compared to $40.9 million a year ago. Basic and diluted net loss per common share were $0.21 compared to $0.39 a year ago.

The company provided financial guidance for full year 2017. For the period, net U.S. Auryxia product sales to be $56 to $60 million.